Patrick Campbell

New data from the POISE-3 trial indicates adherence to a preoperative hypotension avoidance strategy was no more effective than a hypertension-avoidance strategy for reducing risk of postoperative adverse events.

Announced on April 25, 2023, the FDA's clearance of the Omnipod GO marks the first-of-its-kind for a basal-only insulin pod and is indicated for use as an insulin delivery device for people with type 2 diabetes aged 18 or older.

An analysis of data from 3 European countries provides insight into the apparent increase in risk of atrial fibrillation associated with preterm births as well as LGA or SGA births.

Data from the BRAVES trial indicates 70% of patients undergoing metabolic or bariatric surgery with histologically confirmed NASH achieved resolution at 52 weeks.

On April 19, 2023, an expert clinical decision pathway and scientific statement were published simultaneously in JACC. Both of these documents were aimed at providing an overview of heart failure with preserved ejection fraction, including diagnosis and management, based on contemporary evidence.

On April 21, 2023, Medtronic announced the long-awaited US approval of their MiniMed 780G System with Smart Guard Technology and the Guardian 4 Sensor, which has been available in Europe for nearly 3 years.

An analysis of hospitals in the Get With The Guidelines-HF program provides an overview of quality of care for patients treated at hospitals with a high proportion of Black patients relative to other hospitals within the program.

A meta-analysis of trials examining use of the t:slim X2 insulin pump with Control-IQ technology, results of the study indicate use of the hybrid closed loop technology was associated with improvements in glycemic control, regardless of patient age, race, or previous CGM use.

Using data from 4 major phase 3 trials and the Global Burden of Disease Report, investigators detail the potential impact of optimal prescription of SGLT2 inhibitors in heart failure by estimating the number of worsening heart failure events and cardiovascular deaths prevented or postponed as a result of uptake.

Using data from more than 800 older patients, new research is shining a light on the potential reduction in cognitive decline seen with the use of catheter ablation among patients with atrial fibrillation relative to medical management.

A new study leveraging data from 184 countries based on 11 dietary factors provides an overview of the diet attributable burden of type 2 diabetes in the world today.

A single-center study from India sheds light on the safety and efficacy of biosimilar tenecteplase relative to the reference agent for patients with acute ischemic stroke.

A cross-sectional analysis of data is offering a snapshot of trends in the treatment of 7 common chronic health conditions among incarcerated populations in the US relative to the general population.

Announced on April 14, the clearance allows for FreeStyle Libre 3 users to obtain real-time glucose readings on a large, easy-to-see screen directly from their back of arm sensors.

A systematic review and meta-analysis detail the unadjusted odds of developing chemotherapy-related cardiotoxicity among patients who are Black or of African ancestry relative to their White counterparts.

A double-blind, repeated crossover trial suggests personalized treatment for blood pressure could yield an additional 4.4 mmHg reduction in systolic blood pressure.

An analysis of data from national registries in Sweden offers an overview of associations between psychiatric disorders and educational milestone attainment among youth with type 1 diabetes.

A post hoc analysis of the HOST-EXAM trial provides insight into the effects of clopidogrel monotherapy as long-term maintenance therapy relative to aspirin for multiple adverse outcomes in patients with a history of PCI.

A new pilot study assessing the shelf life of insulin when stored at room temperature during the summer in India suggests most insulins maintained 95% potency or greater at 4 months relative to refrigerated insulin.

An analysis of survey data from 500 patients with immune-mediated diseases, including rheumatoid arthritis, psoriasis, and IBD, suggests fewer than 1-in-4 patients were knowledgeable on the concept of biosimilars, but were open to learning more and considering use.

Leveraging data from more than 40,000 Veterans with primary hyperparathyroidism, a new NIA-funded study details the impact of parathyroidectomy on long-term kidney function among these patients.

A retrospective analysis of more than 60 patients 21 years or younger who received a transcatheter leadless pacemaker provides an overview of the safety of such an approach in younger patient populations.

A prospective study of more than 120 patients who underwent bariatric surgery sheds additional light on the potential benefits incurred by undergoing weight loss surgery in people with obesity.

The top 10 most popular FDA approval articles from the first quarter of 2023, with an additional spotlight on other top regulatory news from the first 3 months of the year.

A retrospective, propensity score-matched analysis details significant risk reductions achieved with bariatric surgery in patients with nonalcoholic fatty liver disease and obesity.

Announced on April 6, the recall, which is the most serious of its kind, includes all Readers used with the FreeStyle Libre, FreeStyle Libre 14 day, and FreeStyle Libre 2 Flash Glucose Monitoring Systems distributed from November 2017-February 2023, which totals more than 4 million devices in the US.

An analysis of data from patients in the DELIVER and DAPA-HF trials in the Americas provides an overview of the benefits of dapagliflozin in Black patients relative to White patients.

An analysis of more than 2 dozens studies provides and overview of the evolving safety profile of balloon pulmonary angioplasty in the treatment of chronic thromboembolic pulmonary hypertension in a period lasting from 2013-2022.

Leveraging data from the PADIT trial, investigators provide an overview of the impact of extent and timing of infections following cardiac implantable electronic device implantation.

Data from the ARCHITECT trial detail the effects of alirocumab use on coronary plaque burden and characteristics in a cohort of patients with familial hypercholesterolemia but without atherosclerotic cardiovascular disease.